Lena Biosciences specializes in developing cutting-edge 3D tissue models that transform cell-based assays into physiologically predictive tools. The company serves pharmaceutical companies, research institutions, and biotechnology firms, operating in the biomedical and pharmaceutical testing markets. Lena Biosciences employs a business-to-business (B2B) model, generating revenue through the sale of proprietary products such as the Perfused Organ Panel, SeedEZ, and GradientEZ, as well as offering specialized services and distribution partnerships. The company leverages its proprietary hemoglobin analog, Blood Substitute, to enhance the accuracy and reliability of its models. Lena Biosciences is led by CEO Jelena Vukasinovic, an experienced entrepreneur in biotechnology, and Chief Scientific Officer James Shoemaker, a recognized biomedical engineer. The company aims to revolutionize drug development and biomedical research by providing more accurate and predictive testing tools.

Keywords: 3D tissue models, pharmaceutical testing, cell-based assays, biomedical research, Perfused Organ Panel, SeedEZ, GradientEZ, hemoglobin analog, Blood Substitute, biotechnology.